pralsetinib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Blueprint Medicines Corporation (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadcancer therapy

I am/have/hadmeasurable disease

I am/have/hadlung neoplasm

I am/have/hadpulmonary disease

I am/have/hadstage iv nsclc

I am/have/hadmetastatic non-small cell lung cancer

I am/have/hadsmall cell lung cancer

I am/have/hadnon-small cell lung cancer

I am/have/hadlung cancer

I am/have/hadcancer treatment

I am/have/hadstage iv non-small cell lung cancer

I am/have/hadlung disease

I am/have/hadcancer chemotherapy

I am/have/hadbronchogenic carcinoma

I am/have/hadcarcinoma

I am/have/hadneoplasms by site

I am/have/hadchemoradiotherapy

I am/have/hadprogressive disease

I am/have/hadchemotherapy regimen

I am/have/hadcancer

added new label for I am/have/had

more

I am looking for

I am looking forpemetrexed

I am looking forcarboplatin

I am looking formet inhibitor

I am looking forpralsetinib

I am looking forret inhibitor

I am looking forimmunostimulants

I am looking forcisplatin

I am looking forgemcitabine

I am looking forimmunomodulator

I am looking forplatinum-based chemotherapy

I am looking forpembrolizumab

I am looking foradjuvant

I am looking forimmunomodulators

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 3
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Endocrinology
Recruiting

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

measurable disease

pulmonary disease

stage iv nsclc

cancer therapy

lung neoplasm

0 views
19 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2026 All rights reserved.